Published in Drug Law Weekly, February 8th, 2005
Under the terms of the nonexclusive agreement, Cambrex Bio Science will develop telomerized (telomerase-immortalized) cell lines and associated products such as media. Cambrex Bio Science will provide the telomerized cells under license to customers for life science research, including drug-development activities such as toxicity testing and high-throughput screening. Cambrex may also utilize...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.